Studies from 2025 reveal a MYC-USP39-SRSF1 axis driving splice-switching in MM, with high SRSF1 predicting poor prognosis and siRNA targeting showing anti-MM activity [185,186]. This evidence concerns the gene USP39 and Miyoshi myopathy.